These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 32100588)
1. Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics. Kamperschroer C; Shenton J; Lebrec H; Leighton JK; Moore PA; Thomas O J Immunotoxicol; 2020 Dec; 17(1):67-85. PubMed ID: 32100588 [TBL] [Abstract][Full Text] [Related]
2. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305 [TBL] [Abstract][Full Text] [Related]
3. Redirected T Cell Cytotoxicity in Cancer Therapy. Clynes RA; Desjarlais JR Annu Rev Med; 2019 Jan; 70():437-450. PubMed ID: 30379598 [TBL] [Abstract][Full Text] [Related]
4. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release. Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018 [TBL] [Abstract][Full Text] [Related]
5. Quantitative Clinical Pharmacology of T-Cell Engaging Bispecifics: Current Perspectives and Opportunities. Morcos PN; Li J; Hosseini I; Li CC Clin Transl Sci; 2021 Jan; 14(1):75-85. PubMed ID: 32882099 [TBL] [Abstract][Full Text] [Related]
6. Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy. Iwata Y; Sasaki M; Harada A; Taketo J; Hara T; Akai S; Ishiguro T; Narita A; Kaneko A; Mishima M Toxicol Appl Pharmacol; 2019 Sep; 379():114657. PubMed ID: 31326447 [TBL] [Abstract][Full Text] [Related]
7. Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. Hosseini I; Gadkar K; Stefanich E; Li CC; Sun LL; Chu YW; Ramanujan S NPJ Syst Biol Appl; 2020 Aug; 6(1):28. PubMed ID: 32859946 [TBL] [Abstract][Full Text] [Related]
8. An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection. Saber H; Del Valle P; Ricks TK; Leighton JK Regul Toxicol Pharmacol; 2017 Nov; 90():144-152. PubMed ID: 28887049 [TBL] [Abstract][Full Text] [Related]
9. A Modeling Framework to Characterize Cytokine Release upon T-Cell-Engaging Bispecific Antibody Treatment: Methodology and Opportunities. Chen X; Kamperschroer C; Wong G; Xuan D Clin Transl Sci; 2019 Nov; 12(6):600-608. PubMed ID: 31268236 [TBL] [Abstract][Full Text] [Related]
10. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751 [TBL] [Abstract][Full Text] [Related]
11. Overcoming the challenges associated with CD3+ T-cell redirection in cancer. Singh A; Dees S; Grewal IS Br J Cancer; 2021 Mar; 124(6):1037-1048. PubMed ID: 33469153 [TBL] [Abstract][Full Text] [Related]
15. Nonclinical Investigation of Cytokine Mitigation Strategies for T-cell-Engaging Bispecifics in the Cynomolgus Macaque. Kamperschroer C; Guffroy M; Shen A; Dokmanovich M; Stubbs M; O'Donnell LM J Immunother; 2024 Jun; 47(5):160-171. PubMed ID: 38562119 [TBL] [Abstract][Full Text] [Related]
16. CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. Li J; Piskol R; Ybarra R; Chen YJ; Li J; Slaga D; Hristopoulos M; Clark R; Modrusan Z; Totpal K; Junttila MR; Junttila TT Sci Transl Med; 2019 Sep; 11(508):. PubMed ID: 31484792 [TBL] [Abstract][Full Text] [Related]
17. Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors. Geva R; Vieito M; Ramon J; Perets R; Pedregal M; Corral E; Doger B; Calvo E; Bardina J; Garralda E; Brown RJ; Greger JG; Wu S; Steinbach D; Yao TS; Cao Y; Lauring J; Chaudhary R; Patel J; Patel B; Moreno V Cancer Immunol Immunother; 2024 Aug; 73(10):205. PubMed ID: 39105878 [TBL] [Abstract][Full Text] [Related]
18. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma. Panowski SH; Kuo TC; Zhang Y; Chen A; Geng T; Aschenbrenner L; Kamperschroer C; Pascua E; Chen W; Delaria K; Farias S; Bateman M; Dushin RG; Chin SM; Van Blarcom TJ; Yeung YA; Lindquist KC; Chunyk AG; Kuang B; Han B; Mirsky M; Pardo I; Buetow B; Martin TG; Wolf JL; Shelton D; Rajpal A; Strop P; Chaparro-Riggers J; Sasu BJ Mol Cancer Ther; 2019 Nov; 18(11):2008-2020. PubMed ID: 31434693 [TBL] [Abstract][Full Text] [Related]
19. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies. Leclercq G; Haegel H; Schneider A; Giusti AM; Marrer-Berger E; Boetsch C; Walz AC; Pulko V; Sam J; Challier J; Ferlini C; Odermatt A; Umaña P; Bacac M; Klein C J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326166 [TBL] [Abstract][Full Text] [Related]
20. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]